This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Conte, J. E.
Right arrow Articles by Zurlinden, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Conte, J. E., Jr.
Right arrow Articles by Zurlinden, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2004, p. 3823-3827, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.3823-3827.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Intrapulmonary Pharmacokinetics and Pharmacodynamics of Itraconazole and 14-Hydroxyitraconazole at Steady State

John E. Conte Jr.,1,2,3* Jeffrey A. Golden,2 Juliana Kipps,1 Marina McIver,1 and Elisabeth Zurlinden1

Infectious Diseases Research Group, Department of Epidemiology & Biostatistics,1 Department of Medicine,2 Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, California3

Received 30 January 2004/ Returned for modification 1 March 2004/ Accepted 15 June 2004

We determined the steady-state intrapulmonary pharmacokinetic and pharmacodynamic parameters of orally administered itraconazole (ITRA), 200 mg every 12 h (twice a day [b.i.d.]), on an empty stomach, for a total of 10 doses, in 26 healthy volunteers. Five subgroups each underwent standardized bronchoscopy and bronchoalveolar lavage (BAL) at 4, 8, 12, 16, and 24 h after administration of the last dose. ITRA and its main metabolite, 14-hydroxyitraconazole (OH-IT), were measured in plasma, BAL fluid, and alveolar cells (AC) using high-pressure liquid chromatography. Half-life and area under the concentration-time curves (AUC) in plasma, epithelial lining fluid (ELF), and AC were derived using noncompartmental analysis. ITRA and OH-IT maximum concentrations of drug (Cmax) (mean ± standard deviation) in plasma, ELF, and AC were 2.1 ± 0.8 and 3.3 ± 1.0, 0.5 ± 0.7 and 1.0 ± 0.9, and 5.5 ± 2.9 and 6.6 ± 3.1 µg/ml, respectively. The ITRA and OH-IT AUC for plasma, ELF, and AC were 34.4 and 60.2, 7.4 and 18.9, and 101 and 134 µg · hr/ml. The ratio of the Cmax and the MIC at which 90% of the isolates were inhibited (MIC90), the AUC/MIC90 ratio, and the percent dosing interval above MIC90 for ITRA and OH-IT concentrations in AC were 1.1 and 3.2, 51 and 67, and 100 and 100%, respectively. Plasma, ELF, and AC concentrations of ITRA and OH-IT declined monoexponentially with half-lives of 23.1 and 37.2, 33.2 and 48.3, and 15.7 and 45.6 h, respectively. An oral dosing regimen of ITRA at 200 mg b.i.d. results in concentrations of ITRA and OH-ITRA in AC that are significantly greater than those in plasma or ELF and intrapulmonary pharmacodynamics that are favorable for the treatment of fungal respiratory infection.

* Corresponding author. Mailing address: University of California, San Francisco, 350 Parnassus Ave., Suite 507, San Francisco, CA 94117. Phone: (415) 476-1312. Fax: (415) 476-0760. E-mail: 1jconte99{at}comcast.net.

Antimicrobial Agents and Chemotherapy, October 2004, p. 3823-3827, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.3823-3827.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Crandon, J. L., Banevicius, M. A., Fang, A. F., Crownover, P. H., Knauft, R. F., Pope, J. S., Russomanno, J. H., Shore, E., Nicolau, D. P., Kuti, J. L. (2009). Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults. Antimicrob. Agents Chemother. 53: 5102-5107 [Abstract] [Full Text]  
  • Weiler, S., Falkensammer, G., Hammerer-Lercher, A., Anliker, M., Vogelsinger, H., Joannidis, M., Dunzendorfer, S., Stein, M., Bellmann, R. (2009). Pulmonary Epithelial Lining Fluid Concentrations after Use of Systemic Amphotericin B Lipid Formulations. Antimicrob. Agents Chemother. 53: 4934-4937 [Abstract] [Full Text]  
  • Nicasio, A. M., Tessier, P. R., Nicolau, D. P., Knauft, R. F., Russomanno, J., Shore, E., Kuti, J. L. (2009). Bronchopulmonary Disposition of Micafungin in Healthy Adult Volunteers. Antimicrob. Agents Chemother. 53: 1218-1220 [Abstract] [Full Text]  
  • Conte, J. E. Jr., Golden, J. A., Krishna, G., McIver, M., Little, E., Zurlinden, E. (2009). Intrapulmonary Pharmacokinetics and Pharmacodynamics of Posaconazole at Steady State in Healthy Subjects. Antimicrob. Agents Chemother. 53: 703-707 [Abstract] [Full Text]  
  • Kiem, S., Schentag, J. J. (2008). Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid. Antimicrob. Agents Chemother. 52: 24-36 [Full Text]  
  • Abdel-Rahman, S. M., Jacobs, R. F., Massarella, J., Kauffman, R. E., Bradley, J. S., Kimko, H. C., Kearns, G. L., Shalayda, K., Curtin, C., Maldonado, S. D., Blumer, J. L. (2007). Single-Dose Pharmacokinetics of Intravenous Itraconazole and Hydroxypropyl-{beta}-Cyclodextrin in Infants, Children, and Adolescents. Antimicrob. Agents Chemother. 51: 2668-2673 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»